If you have been reading about thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
| Property | Value | Notes |
|---|---|---|
| Reconstitution solvent | Sterile water or aqueous buffer | Aseptic technique recommended |
| Post-reconstitution storage | 2–8 °C short term; frozen for longer periods | Avoid repeated freeze-thaw cycles |
| Typical purity assay | Reversed-phase HPLC | Peak area used to estimate purity |
| Identity confirmation | Mass measurement | Compares observed value with expected mass |
| Main degradation routes | Hydrolysis and oxidation | Accelerated by heat and extreme pH |
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Trump tells reporters that US forces shot down seven Iranian "fast boats". May 5 Iran War: U.S. Secretary of State Marco Rubio announces that Operation Epic Fury has concluded. President Trump announces that Operation Project Freedom has been paused, citing progress in negotiations. CNN hosts the California gubernatorial primary debate. Vivek Ramaswamy wins the Republican nomination for the governor of Ohio. Tanner Horner is sentenced to death after pleading guilty to the murder of Athena Strand, a 7-year-old girl he took from her Texas home while delivering a Christmas gift. May 6 Iran war: Amid negotiations over the Strait of Hormuz crisis, President Trump says that the U.S. and Israeli war against Iran could end if Iran accepts a U.S. proposal, but warns that bombing would resume at "a much higher level and intensity" if it rejects the terms. Iran says it is reviewing the proposal. Former collegiate American football quarterback Stephen Garcia, who played for the University of South Carolina, announces he has been diagnosed with stage IV colorectal cancer. May 7 – The U.S. Department of State along with other federal agencies orders an investigation of all 53 Mexican consulates throughout the country. The Trump administration accuses former Mexican President Andrés Manuel López Obrador of utilizing Mexican consulates in the U.S. to monitor political activities. May 8 Tariffs in the second Trump administration: The U.S. Court of International Trade rules that the 10% global tariffs imposed by Trump are illegal.
Aspartate transaminase (AST) or aspartate aminotransferase, also known as AspAT/ASAT/AAT or (serum) glutamic oxaloacetic transaminase (GOT, SGOT), is a pyridoxal phosphate (PLP)-dependent transaminase enzyme (EC 2.6.1.1) that was first described by Arthur Karmen and colleagues in 1954. AST catalyzes the reversible transfer of an α-amino group between aspartate and glutamate and, as such, is an important enzyme in amino acid metabolism. AST is found in the liver, heart, skeletal muscle, kidneys, brain, red blood cells and gall bladder. Serum AST level, serum ALT (alanine transaminase) level, and their ratio (AST/ALT ratio) are commonly measured clinically as biomarkers for liver health. The tests are part of blood panels. The half-life of total AST in the circulation approximates 17 hours and, on average, 87 hours for mitochondrial AST. Aminotransferase is cleared by sinusoidal cells in the liver. Aspartate transaminase catalyzes the interconversion of the natural amino acid, L-aspartic acid and α-ketoglutaric acid to give oxaloacetic acid and L-glutamic acid.:
In addition, if a piece of wood is used for multiple purposes, there may be a significant delay between the felling of the tree and the final use in the context in which it is found. This is often referred to as the "old wood" problem. One example is the Bronze Age trackway at Withy Bed Copse, in England; the trackway was built from wood that had clearly been worked for other purposes before being re-used in the trackway. Another example is driftwood, which may be used as construction material. It is not always possible to recognize re-use. Other materials can present the same problem: for example, bitumen is known to have been used by some Neolithic communities to waterproof baskets; the bitumen's radiocarbon age will be greater than is measurable by the laboratory, regardless of the actual age of the context, so testing the basket material will give a misleading age if care is not taken. A separate issue, related to re-use, is that of lengthy use, or delayed deposition. For example, a wooden object that remains in use for a lengthy period will have an apparent age greater than the actual age of the context in which it is deposited.
The causes of autism are a subject of scientific research, but understanding of the etiology of autism is incomplete. It is influenced by a complex interplay of genetic, epigenetic, prenatal, perinatal, and environmental factors. Genetics play a major role, with heritability estimates ranging from 60–90%. De novo mutations—including copy number variations and gene-disrupting mutations—contribute to approximately 30–40% of cases. However, most autism cases involve complex interactions among multiple inherited genetic variants, many of which are still unknown. Epigenetic mechanisms, such as DNA methylation and genomic imprinting, also influence gene expression and susceptibility, often interacting with environmental exposures. In rare cases, autism has been associated with agents that cause birth defects. Prenatal risk factors include advanced parental age, maternal metabolic or autoimmune disorders, infections, and prenatal stress, while perinatal risks involve preterm birth, low birth weight, and birth complications. Postnatal mechanisms have been proposed, including immune dysregulation, gastrointestinal abnormalities, oxidative stress, and neural circuit differences, though these remain largely unproven and are the focus of ongoing research. Some Neanderthal-derived genetic variants may influence susceptibility. Current high-quality evidence shows no causal link between prenatal use of paracetamol and autism. Overwhelming scientific evidence shows no causal association between thiomersal and vaccines, including the measles-mumps-rubella (MMR) vaccine, and autism.
Sources: en.wikipedia.org
== External links == Olfactory Receptor Database Archived 2007-02-19 at the Wayback Machine Human Olfactory Receptor Data Exploratorium (HORDE) Olfactory+Receptor+Protein at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
== March 2016 reconstitution == In December 2015, Kim Hames announced his intention to resign as deputy leader of the Liberal Party (and thus also as deputy premier) with effect from February 2016. Liza Harvey was elected unopposed as his successor, with a resultant ministerial reshuffle that took effect from 31 March 2016. Another reshuffle took place on 22 September 2016, with the resignations of Dean Nalder and Tony Simpson. All ministers are listed in order of seniority.
=== Environmental and health hazards === Synthetic phenolic antioxidants (SPAs) and aminic antioxidants have potential human and environmental health hazards. SPAs are common in indoor dust, small air particles, sediment, sewage, river water and wastewater. They are synthesized from phenolic compounds and include 2,6-di-tert-butyl-4-methylphenol (BHT), 2,6-di-tert-butyl-p-benzoquinone (BHT-Q), 2,4-di-tert-butyl-phenol (DBP) and 3-tert-butyl-4-hydroxyanisole (BHA). BHT can cause hepatotoxicity and damage to the endocrine system and may increase the carcinogenicity of 1,1-dimethylhydrazine exposure. BHT-Q can cause DNA damage and mismatches through the cleavage process, generating superoxide radicals. DBP is toxic to marine life if exposed long-term. Phenolic antioxidants have low biodegradability, but they do not have severe toxicity toward aquatic organisms at low concentrations. Another type of antioxidant, diphenylamine (DPA), is commonly used in the production of commercial, industrial lubricants and rubber products and it also acts as an additive for automotive engine oils.
==== MeSH E05.200.750 – histological techniques ==== MeSH E05.200.750.132 – autoradiography MeSH E05.200.750.210 – bone demineralization technique MeSH E05.200.750.288 – decalcification technique MeSH E05.200.750.551 – histocytochemistry MeSH E05.200.750.551.512 – immunohistochemistry MeSH E05.200.750.551.512.240 – fluorescent antibody technique MeSH E05.200.750.551.512.240.300 – fluorescent antibody technique, direct MeSH E05.200.750.551.512.240.310 – fluorescent antibody technique, indirect MeSH E05.200.750.551.790 – periodic acid-schiff reaction MeSH E05.200.750.551.810 – prussian blue reaction MeSH E05.200.750.600 – histocytological preparation techniques MeSH E05.200.750.600.520 – microdissection MeSH E05.200.750.600.530 – microtomy MeSH E05.200.750.600.530.160 – cryoultramicrotomy MeSH E05.200.750.600.530.160.260 – frozen sections MeSH E05.200.750.600.620 – replica techniques MeSH E05.200.750.600.620.150 – corrosion casting MeSH E05.200.750.600.620.260 – freeze fracturing MeSH E05.200.750.600.620.260.400 – freeze etching MeSH E05.200.750.600.670 – staining and labeling MeSH E05.200.750.600.670.130 – chromosome banding MeSH E05.200.750.600.670.325 – in situ hybridization MeSH E05.200.750.600.670.325.350 – in situ hybridization, fluorescence MeSH E05.200.750.600.670.325.350.125 – chromosome painting MeSH E05.200.750.600.670.325.680 – primed in situ labeling MeSH E05.200.750.600.670.520 – negative staining MeSH E05.200.750.600.670.620 – periodic acid-schiff reaction MeSH E05.200.750.600.670.660 – prussian blue reaction MeSH E05.200.750.600.670.770 – shadowing (histology) MeSH E05.200.750.600.670.780 – silver staining MeSH E05.200.750.600.720 – tissue embedding MeSH E05.200.750.600.720.610 – paraffin embedding MeSH E05.200.750.600.720.640 – plastic embedding MeSH E05.200.750.600.760 – tissue preservation MeSH E05.200.750.600.760.160 – cryopreservation MeSH E05.200.750.600.760.160.260 – freeze drying MeSH E05.200.750.600.760.160.260.270 – freeze substitution MeSH E05.200.750.600.760.720 – tissue fixation
De = 0.8 × 100 mg = 80 mg That is the 100 mg administered represents a blood plasma concentration of 80 mg that has the capacity to have a pharmaceutical effect. This concept depends on a series of factors inherent to each drug, such as:
Sources: en.wikipedia.org
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.
There is no broadly accepted figure for TB-500. Laboratory practice is short-term storage at 2–8 °C with longer-term aliquots frozen, and degradation is expected to increase with time and temperature. Users typically rely on their own stability checks rather than published data.
Mass measurement provides the clearest confirmation by matching an observed value to the expected one. Reversed-phase chromatography adds a purity estimate through peak integration. Combining both is standard because neither alone establishes identity and purity together.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.